These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19098969)

  • 21. Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms.
    Sayre EC; Bunting PS; Kopec JA
    Can J Urol; 2009 Feb; 16(1):4463-71. PubMed ID: 19222884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.
    Punnen S; Nam RK
    Surg Oncol; 2009 Sep; 18(3):192-9. PubMed ID: 19282170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results.
    Maestroni U; Ziveri M; Azzolini N; Dinale F; Ziglioli F; Campaniello G; Frattini A; Ferretti S
    Acta Biomed; 2008 Dec; 79(3):211-6. PubMed ID: 19260381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
    Tonita JM; Skarsgard D; Muhajarine N
    Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH; Roobol MJ
    Curr Opin Urol; 2009 May; 19(3):227-31. PubMed ID: 19357513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men.
    Khezri AA; Shirazi M; Ayatollahi SM; Lotfi M; Askarian M; Ariafar A; Afrasiabi MA
    Iran J Immunol; 2009 Mar; 6(1):40-8. PubMed ID: 19293477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer early detection clinical practice guidelines in oncology.
    Babaian RJ; Partin AW;
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S42-55. PubMed ID: 19795575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
    Macefield RC; Lane JA; Metcalfe C; Down L; Neal DE; Hamdy FC; Donovan JL
    Eur J Cancer; 2009 Sep; 45(14):2569-73. PubMed ID: 19375907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer: epidemiology and health-related quality of life.
    Penson DF; Rossignol M; Sartor AO; Scardino PT; Abenhaim LL
    Urology; 2008 Dec; 72(6 Suppl):S3-11. PubMed ID: 19095126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoting prostate-specific antigen informed decision-making. Evaluating two community-level interventions.
    Driscoll DL; Rupert DJ; Golin CE; McCormack LA; Sheridan SL; Welch BM; Poehlman JA
    Am J Prev Med; 2008 Aug; 35(2):87-94. PubMed ID: 18617077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.
    Ito K
    Int J Urol; 2009 May; 16(5):458-64. PubMed ID: 19341365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
    Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
    Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is DRE essential for the follow up of prostate cancer patients? A prospective audit of 194 patients.
    Ragavan N; Sangar VK; Gupta S; Herdman J; Matanhelia SS; Watson ME; Blades RA
    BMC Urol; 2005 Jan; 5():1. PubMed ID: 15642124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients' perceptions of transrectal prostate biopsy: a qualitative study.
    Chapple AB; Ziebland S; Brewster S; McPherson A
    Eur J Cancer Care (Engl); 2007 May; 16(3):215-21. PubMed ID: 17508940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What influences men's decision to have a prostate-specific antigen test? A qualitative study.
    Rai T; Clements A; Bukach C; Shine B; Austoker J; Watson E
    Fam Pract; 2007 Sep; 24(4):365-71. PubMed ID: 17644829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer: screening, diagnosis and management in 2007.
    Grubb RL; Kibel AS
    Mo Med; 2007; 104(5):408-13; quiz 413-4. PubMed ID: 18018527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do changes in a high serum prostate-specific antigen level and the free/total prostate-specific antigen ratio after antibiotic treatment rule out biopsy and the suspicion of cancer?
    Dirim A; Tekin MI; Koyluoglu E; Oguzulgen AI; Peskircioglu L; Ozkardes H
    Urol Int; 2009; 82(3):266-9. PubMed ID: 19440011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.